经胸腔置管导入尿激酶在结核性渗出性胸膜炎治疗中的临床应用研究

Clinical Application Research of The Catheter Into Urokinase Chest in Treatment of Tuberculous Exudative Pleurisy

目的探讨经胸腔置管导入尿激酶在结核性渗出性胸膜炎治疗中的临床应用价值。方法收集98例2008年2月至2010年2月期间住新乡医学院第一附属医院的结核性渗出性胸膜炎患者,随机分为两组,综合组、对照组各49例,记录两组的临床症状,药物不良事件。疗效判定显效或无效,并进行χ2检验的统计学分析。结果两组的人数、性别、临床表现、胸水量和病情程度,统计分析无显著差异(P>0.05),两组之间具有可比性。比较两组有效率,差异有统计学意义(χ2=6.31,P<0.05)。结论在药物治疗的基础上联合经胸腔置管导入尿激酶,可以很快缓解患者临床症状,胸水消失迅速,效果显著,患者耐受性好,提高了患者的生活质量,改善患者预后,值得临床推广。

Objective To explore the catheter into urokinase chest in the treatment of tuberculous exudative pleurisy clinical application value.Methods Collecting 98 cases in February 2008 to February 2010 during live in First Affiliated Hospital of Xinxiang Medical College,tuberculous exudative pleurisy patients were randomly divided into two groups,and control,maintaining the 49 cases,record two groups of clinical symptoms,drug adverse events.Outcome powerfully or invalid χ2 test,and the statistical analysis.Results The two groups of toll,sex,clinical manifestation,chest water and illness degree,statistical analysis no significant difference（P〉 0.05）,two groups comparable.Compare two sets of efficient,difference was statistically significant（χ2 = 6.31,P〈0.05）.Conclusion In drug treatment on the basis of the catheter into joint urokinase chest,can quickly alleviate clinical symptoms,hydrothorax disappear rapidly,remarkably,superior tolerability,improve the patients,improve the quality of life of the patients,worth the prognosis of patients with clinical promotion.